Infections Caused by Extended-Spectrum β-Lactamase Producing Escherichia Coli in Systemic Lupus Erythematosus Patients: Prevalence, Risk Factors, and Predictive Model

Table 2

The antimicrobial susceptibility patterns of ESBL producing and nonproducing strains to various antimicrobials, n(%).

Antibiotics	Total	ESBL (+)	ESBL (-)	P value
	n=384	n=212	n=172
Ampicillin	46 (11.9)	0 (0)	46 (27.8)	<0.001
Piperacillin	54 (14.1)	0 (0)	54 (31.4)	<0.001
Ampicillin-sulbactam	120 (31.3)	26 (12.3)	94 (54.7)	<0.001
Piperacillin-tazobactam	346 (90.1)	174 (82.1)	172 (100)	<0.001
Ciprofloxacin	110 (28.6)	20 (9.4)	90 (52.3)	<0.001
Levofloxacin	70 (18.2)	0 (0)	70 (40.7)	<0.001
cefuroxime	114 (29.7)	0 (0)	114 (66.3)	<0.001
ceftazidime	228 (59.4)	56 (26.4)	172 (100)	<0.001
cefepime	226 (58.9)	80 (37.7)	146 (84.9)	<0.001
Aztreonam	260 (67.7)	88 (41.5)	172 (100)	<0.001
Amikacin	354 (92.2)	190 (89.6)	164 (95.3)	0.230
Gentamicin	214 (55.7)	100 (47.2)	114 (66.3)	0.008
Fosfomycin	310 (80.7)	138 (65.1)	172 (100)	<0.001
Trimethoprim-sulfamethoxazole	140 (36.5)	58 (27.4)	82 (47.7)	0.004
Ertapenem	344 (89.6)	172 (81.1)	172 (100)	<0.001
Meropenem	378 (98.4)	206 (97.2)	172 (100)	0.254
Imipenem	378 (98.4)	206 (97.2)	172 (100)	0.254

ESBL, Extended-Spectrum -Lactamase.